Asia

Todos Medical Ltd. announced positive results from a pre-specified interim analysis of 20 subjects from an ongoing 40-subject outpatient study evaluating the relationship between LymPro Test™ scores with amyloid PET imaging scores.

MIT’s Research Enterprise in Singapore, SMART, launches a new research group, Critical Analytics for Manufacturing Personalized-Medicine (CAMP), as part of Singapore’s National Cell Manufacturing Initiative to overcome scientific and technical challenges in life-changing cell therapies.

Companies from across Europe, Asia and around the globe share pipeline and business updates.

Part of the problem with developing Alzheimer’s drugs has also been that the disease is still not well understood. What is known is that problems with cellular functions and/or improperly functioning proteins cause brain cells, called neurons, to become damaged, leading to their decreased function and eventually death.

An immunotherapy specialist is leveraging the advantages of investing in a new Quantum bioprocessing pump from Watson-Marlow Fluid Technology Group (WMFTG).

Prestige BioPharma announced positive results from a Phase I clinical trial evaluating the pharmacokinetics, safety and immunogenicity of biosimilar candidate HD204 to Avastin.

Prestige BioPharma and Pharmapark LLC announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.

Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area.

“I believe the next Google-level company in healthcare could come from China,” stated Jackson Zhu Weiyan, chief executive officer and founder of My Bio-Med. “China is truly embracing innovation.”

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops and commercializes high quality medicines, presented the research data on the treatment of relapsed or refractory extranodal NK/T cell lymphoma with sintilimab, co-developed with Eli Lilly and Company and key data from six other clinical studies were presented at the 55th Annual Meeting of the American Society of Clinical Oncology by oral presentation and posters.